Professional
Added to YB: 2025-02-05
Pitch date: 2025-01-28
INDV [bullish]
Indivior PLC
+189.58%
current return
Author Info
No bio for this author
Company Info
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Market Cap
GBP 1.2B
Pitch Price
GBP 12.28
Price Target
N/A
Dividend
N/A
EV/EBITDA
3.72
P/E
-25.44
EV/Sales
1.01
Sector
Pharmaceuticals
Category
growth
Summers Value Partners Portfolio Holding: Indivior PLC
INDV: Long-acting opioid addiction drug Sublocade sales forecast cut due to Brixadi competition. Expect approval of improved dosing sNDA in Feb to level field. Long-acting agents underpenetrated at 5-6% of prescriptions. Bought at $7.74/share, 10x expected EPS.
Read full article (1 min)